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ABSTRACT: 
Malaria is a tropical disease caused by parasites from Plasmodium vivax, which are 
normally associated with Anopheles spp. In 2016, an estimated 216 million cases occurred 
worldwide, causing 445 000 deaths. N-myristoyltransferase (NMT) is a very important 
enzyme related with the transfer of myristate acid from myristoyl coenzyme A to specific 
proteins in the glycine N-terminal residue, this process occurs at the same time of the 
translation, for this, aminopeptidases withdraw the initial methionine, making glycine the 
N-terminal amino acid. NMT inhibition demonstrated to leads parasite to cell death. To 
predict new potential inhibitors against NMT Plasmodium, Computer-Aided Drug Design 
(CADD) tools were used to alignment of pharmacophores, virtual screening, validation, 
docking and molecular dynamics. 
Key words: Plasmodium, N-myristoyltransferase, Bioinformatics. 
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1. INTRODUCTION: 
 1.1 Malaria 
Malaria is a tropical disease caused by parasites from Plasmodium vivax, which are 
normally associated with Anopheles spp. After the mosquito bite, the parasite shows the 
capacity to reach the liver and multiply quickly infecting erythrocytes after incubation period, 
which can range between 8 and 30 days causing serious symptoms such as: muscle and 
abdominal pain, fever, fatigue, nausea and diarrhea, tremors and vomiting. These parasite can 
also be transmitted through blood transfusions, transplants or by sharing contaminated syringes 
(ANVISA, 2008). 
 In 2016, an estimated 216 million cases occurred worldwide, of these cases 445 000 
deaths, and an estimated US$ 2.7 billion was spent to control and elimination of malaria in 
endemic places, like Africa, which approximately 90% of malaria cases in 2016 occurred. The 
number of reported malaria cases in Brazil has decreased from 423,000 cases in 2010 to 157,100 
in 2016 and the number of deaths has decreased from 76 cases in 2010 to 37  in 2016 (WHO, 
2017). 
The first records of malaria date back to 2.700 b.C. with the mention of prolonged fevers 
and melancholies. Described by the Canon of Chinese medicine, Nei Ching. The disease has 
been described over the centuries by numerous historical figures like: Plato, Homer and 
Shakespeare, being that Hippocrates was the first to do the connection between proximity to 
standing water and the incidence of fever in population. The word malaria comes from Italian 
origin (mal’aria) because in the XIV century there was a belief that the disease was transmitted 
by marshes and contained air (FRANÇA; DOS SANTOS; FIGUEROA-VILLAR, 2008). 
One of the most important cases of malaria was registered in 1638, when the Countess 
of Chinchón was afflicted with a strong “terçan” fever. The Indians medicated her with a 
mixture of herbs called "quina-quina", which resulted in the cessation of fever and the cure. 
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The Jesuit priests of the Spanish mission eventually took with them the powder that had been 
used to produce the potion by the natives, which became known as the "Jesuit powder" 
presenting Quinone’s, the first known treatment against the parasite (DE OLIVEIRA; 
SZCZERBOWSKI, 2009) 
  The drugs resistance has been one of the major problems in the treatment issue, since 
the administration of only one drug favors selective pressures selecting the resistant mutant 
parasites. Thus, the literature suggests that the use of drugs cocktails reduce the probability of 
emergence of resistant strains (HASTINGS; DONNELLY, 2005). 
The gold standard of malaria treatment consists in artemisinin and Synthetic derivatives, 
but this treatment has shown a loss of efficiency (DAS et al., 2009). 
1.2 N-myristoyltransferase and motivation 
With the artemisinin loss of efficacy new drugs with different mechanisms of action 
have been sought, such as the inhibition of  N-myristoyltransferase (NMT)(YU et al., 2012).  
N-myristoyltransferase (NMT) is a very important enzyme in eukaryotes, highly 
conserved structure among species, however inhibitors of this enzyme may be selective for 
Plasmodium due to the ability of Homo sapiens N-myristoyltransferase 1(HsNMT1) to tolerate 
conformational changes, besides, the overexpression of HsNMT1 and HsNMT2 has been 
shown to be related to carcinomas and viral replication. (TATE et al., 2014). The NMT 
catalyzes a bi-bi mechanism: The covalent transfer of myristate acid from myristoyl coenzyme 
A to specific proteins such tyrosine kinases, G-proteins, and other heterodimer proteins, in the 
glycine N-terminal residue, this process occurs at the same time of the translation, for this, 
aminopeptidases withdraw the initial methionine, making glycine the N-terminal amino acid 
(Figure 1) (WRIGHT et al., 2010; ZHAO; MA, 2014).  
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Figure 1-Bi-Bi mechanism of NMT catalytic cycle (ZHAO; MA, 2014). 
NMT inhibition induces parasite cell death, since the myristylation is involved with 
regulation of protein complex and stability (WRIGHT et al., 2014). Besides, NMT  showed to 
be important in signaling pathway in mice during the early development (YANG et al., 2005). 
NMT was described for the first time in 1987, in Saccharomyces cerevisiae(TOWLER 
et al., 1987). In 2000 the first isolation of NMT from Plasmodium spp. has been shown, 
curiously it had only one form, differently to all metazoan, which exhibit two isoforms of this 
enzyme (TATE et al., 2014). 
NMT is also expressed in humans, which could be a hindrance however according to 
(YU et al., 2012) the residue Y296 is the key to the selectivity between Homo sapiens NMT 
and PvNMT caused by the interaction Y296 and inhibitor. 
The motivation of this work is to provide a new potential target to treat malaria, since 
chloroquine has lost efficacy and artemisinin compounds has shown an emerging resistance 
against Plasmodium falciparum and vivax (DAS et al., 2009). 
 
 4 
 
1.3 Computer-Aided Drug Design 
For a new drug to reach the market a lot of bench test are required, which require long 
time frames and resources, thereat arises the need to use bioinformatics tools that permit to 
realize a filter in the bench tested compounds, increasing the efficiency and efficacy of the 
method, this methodology is called Computer-Aided Drug Design (ACDD), which aim to 
determine interatomic distance, electronic densities, evaluating the conformational equilibrium 
of the molecules and their minimum energy, Allowing to evaluate specific interactions of the 
drugs based on pharmacophores points, which were described at the first time by Ehrlich in 
1909 as a molecular structure that carries essential characteristics for biological activity, this 
definition was  updated in 1998 by IUPAC for a set of steric and electronic characteristics 
necessary to ensure optimal supramolecular interactions with a specify biological agent and to 
trigger or block their biological response. (BARREIRO et al., 1997; EHRLICH, 1909; OOMS, 
2000; WERMUTH et al., 1998). 
 
2.OBJECTIVES: 
 2.1 General objective 
 Predict potential ligands against PvNMT using known compounds libraries and 
bioinformatics tools. 
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 2.2 Specific objectives   
• Perform an alignment with known inhibitors against NMT vivax. 
• Create a shape-based model based on the alignment of the ligand.  
• Create potential decoys using known inhibitors. 
• Perform a shape-based model validation. 
• Perform a virtual screening using known libraries. 
• Perform molecular docking of the best ligands. 
• Selection of the best ligand according to the toxicity parameters. 
• Simulate molecular dynamics of the best complexes 
• Evaluate the protein-ligand in interactions. 
3.MATERIAL AND METHODS: 
3.1 Getting NMT, inhibitors and libraries 
The known protein-ligand complex structures of NMT from P. vivax were retrieved 
from Protein Data Bank (PDB). Six PBD protein-inhibitors complexes were chosen: 4B12, 
4B13, 4B14, 4BBH, 4CAE and 4CAF. Plasmodium vivax NMT (PvNMT) structures were used 
due to absence of Plasmodium falciparum (PfNMT) crystallography in 2016 . According to Yu 
et al., (2012) PvNMT shares 81% identity of the sequence with PfNMT, which suggests that 
PvNMT can be used as model to PfNMT. The compound libraries used on the virtual screening 
were retrieved from ZINC (IRWIN; SHOICHET, 2005) and Chembridge (Corporation, San 
Diego, California) Databases. Two subsets, ZDD, a library of commercially available approved 
drugs from ZINC and EXP, a stringent library of druglike compounds from Chembridge were 
used. 
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3.2 Getting shape-based model 
PharmaGist webserver (DROR et al., 2009) was used to provide a pharmacophore 
alignment using known inhibitors against NMT extracted from PDB complexes 4B12, 4B13, 
4B14, 4BBH, 4CAE and 4CAF. Alignments with the best pharmagist score were submitted to 
vRocs(HAWKINS; SKILLMAN; NICHOLLS, 2007), to create shape-based models 
3.3 Model validation 
In order to validate the shape-based models known inhibitors  based on Bell et al (2012) 
were used. The inhibitors used   are indicated in the Table 1, all 10 structures were design using 
PubChem Draw Structure (KIM et al., 2016) in SMILES format. 
Table 1-SMILES format of known inhibitors against NMT. 
C1=CC=C(C(=C1)C(=O)N([C@H]2CN(CC2)C(CN(C)C)=O)[H])C(F)(F)F 
C1=C(C=C(C=C1C2CCN(CC2)CC4=NC3=CC(=CC=C3[N]4C)C)F)F 
C1=CC=CC(C1C)C2=CCC3C(=C2)C(=NN3C)CN(C)C 
C1(=CC(=C(C=C1)CN(C(=O)C2CN(C2)C3=C(C=NC(=N3)N(CCN(C)C)C)Cl)[H])F)F 
N(C(=O)C1CN(C1)C2=C(C=NC(=N2)N(CCN(C)C)[H])Cl)(CC3=NC=C(N=C3)C)[H] 
C1=C(C=CC=N1)CCN(CC2=CC(=CC=C2)C3=CC=CC(=C3)CN4CC5C(CC4)N=CS5)[H] 
C1=CC(=CC=C1[C@@H]2[C@H](CN(C2)C(C[C@@H](CC3=CC=C(C=C3)Cl)N([H])[H])=O)CO[H])CC 
C1CC(CCN1C)N(C)C2=NC3=C(C(=N2)N(CCC#C)C)SC(=C3)C 
C1C(CCN(C1)[H])C2=C[N](C3=C2C=C(C=C3)N(C(CC4=CC=C(C=C4)F)=O)[H])[H] 
C1=CC(=CC=C1)Cl.C2[C@H](CN(C2)C(C[C@@H](CC3=CC=C(C=C3)Cl)N([H])[H])=O)CO[H] 
 
DUD-E webtool (MYSINGER et al., 2012) was used to predict decoys using known 
inhibitors (Table 1), decoys are structures that have similar proprieties with ligand but different 
chemical structure. To perform the validation using shape-based models, decoys (compounds 
that can bind but have no response) and actives structures were submitted to a comparative 
virtual screening. Previously actives and decoys were prepared using QUACPAC (OpenEye 
Scientific Software, Santa Fe, NM. http://www.eyesopen.com) to generate tautomer’s and to 
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protonate ligand states to physiological pH 7.4. Besides, Omega (HAWKINS et al., 2010) was 
used to generate 3D  bioactive conformers for each molecule 
3.4 Libraries preparation. 
 The EXP is a library extracted from ChemBrigde, which have chemical compounds 
with drug likeness proprieties. ZDD library was extracted from ZINC and have natural 
compounds that are already drugs.   
In active and ligand preparation step the EXP and ZDD were prepared using 
QUACPAC. Further  Omega (HAWKINS et al., 2010) were  used in order to filter compounds 
with druglike features and generate 3D conformers for each molecule. 
 
3.5 Virtual Screening and docking. 
Virtual screening using shape-based model were performed on vROCS. The best 500 
compounds were selected using Tanimoto combo score. In the next step a  molecular   docking 
was performed between NMT and 500 best compounds using FRED (MCGANN, 2011).  
3.6 Pharmacokinetics 
Pharmacokinetics analysis were analyzed using  PKCSM (PIRES; BLUNDELL; ASCHER, 
2015), a machine-learn platform, which relies on distance/pharmacophore patterns encoded as 
graph-based signature. In this work was choose some toxicity parameters, such as: AMES 
toxicity, Max tolerated dose (human), hERG I inhibitor, hERG II inhibitor, Oral Rate Acute 
Toxicity (LD50), Oral Rat Chronic Toxicity (LOAEL), Hepatotoxicity and Minnow toxicity.  
The AMES toxicity parameter is used to predict a potential mutagenic compound using in 
bacteria, so if the test is positive, it shows that the compound in question is mutagenic.  
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The Maximum Tolerated Dose (human) parameter estimate the toxic dose threshold of 
chemical in humans (mg/kg/day), being less or equal to 0.477 (mg/kg/day) considered as low 
and high if greater than 0.477 (mg/kg/day).  
The hERG I parameter analyses higher risks to develop the long QT syndrome (LQTS) in 
human, which is a heart rhythm disorder that can cause chaotic and rapid heartbeat. It tests if it 
generates an inhibition of the potassium channels, altering the heartbeat frequency and order. 
The Oral Rate Acute Toxicity (LD50) is the lethal dosage values that is necessary to cause 
the death of 50% of a group of tests  
The Oral Rat Chronic Toxicity refers to identify the lowest dose of compound that results 
in an observed adverse effect (LOAEL). 
The Hepatotoxicity parameters refers a liver associated side effects observed in humans, 
being able to cause or not.  
The Minnow toxicity: the lethal concentration values (LC50) represent the concentration of 
a molecule necessary to cause the death of 50% of the Flathead Minnows. 
Utilizing toxicity parameters was possible to select the best ligand in each library (EXP, 
ZDD) according to pharmacokinetics (Table 4). 
 
3.7 Molecular Dynamics 
The best compounds of each libraries, according to PKCSM parameters was submitted 
to molecular dynamics in complex of NMT. Topology and parameters for each ligand were 
performed using SwissParam (ZOETE et al., 2011), which uses CHARMM force field. The 
molecular dynamics were performed on GROMACS (ABRAHAM et al., 2015), using 
CHARMM27 force-field, water model chosen was TIP3P. The unit cell was defined as triclinic 
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shape, water and ions were added and energy minimization were performed using 10000 
picoseconds. 
3.8 Protein-ligand 2D interaction 
Protein-ligand Interactions 2D diagrams were  generate using LigPlot+(LASKOWSKI; 
SWINDELLS, 2011). Molecular dynamics frames 0 (first), 500(half) and 1000(last) were 
plotted to evaluate the protein-ligand interactions along time. 
4. RESULTS AND DISCUTION  
 4.1 Alignment and Shape-based model 
  The best result of PharmaGist’s alignment exhibited score 36.000 and 6 ligands (NMT 
inhibitors). Sixteen queries were generated from this alignment using vRocs (HAWKINS; 
SKILLMAN; NICHOLLS, 2007), The query models were edit  manually and validate using 
AUC analysis (Table 2). 
 
Table 2- All queries with the number of pharmacophoric points and area under curve(AUC) 
Query/model number Pharmacophore points AUC 
1 5 0.714 
2 5 0.764 
3 5 0.727 
4 5 0.797 
5 5 0.849 
6 5 0.749 
7 5 0.755 
8 5 0.604 
9 6 0.739 
10 6 0.780 
11 6 0.682 
12 6 0.727 
13* 6 0.880 
14 6 0.842 
15 6 0.845 
16 6 0.743 
*Best query according to AUC analysis 
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The chosen model was the number 13 (Figure 2), according the higher AUC (Figure 3), 
which means area under the curve, it is a simply probability that a randomly chosen active 
ligand instead of inactive ligand. 
 
Figure 2- Shape based model Chosen with 6 pharmacophores points, 3 acceptors, 1 donor, 1 
cation and one ring 
  
Figure 3- ROC curve obtained in the validation of the model. Dashed line indicates aleatory 
results, the red line indicated ROC curve generated, and all area under the curve indicated 
model accuracy. 
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4.2 Shape-based virtual screening and Docking 
Virtual screening was performed using model 13 on vROCS and the libraries EXP and 
ZDD which are derived from ChemBridge and ZINC respectively. From each library virtual 
screening results in the best 500 compounds according to tanimoto combo score. 
Screened libraries were submitted to protein ligand docking using FRED, the 1% best 
docked compounds according to Chemgauss4 score were maintained, 8 ligands from EXP and 
6 from ZDD. The best docked ligands were submitted to pharmacokinetics prediction analyses 
using PKCSM, which calculate proprieties, all-pair shortest paths and use a distance-based 
signature to predict the toxicity parameters (Table 3) 
4.3 Toxicity Analysis. 
The importance of toxicity analysis is to predict if the potential inhibitors presents the 
applicable parameters to drug selection, objectifying a future administration in human 
organism. The results were judged by positive/negative pharmacokinetic characteristics, in this 
work was choose some toxicity parameters, such as: AMES toxicity, Max tolerated dose 
(human), hERG I inhibitor, Oral Rate Acute Toxicity (LD50), Oral Rat Chronic Toxicity 
(LOAEL), Hepatotoxicity and Minnow toxicity (Table 3), selected ligands Exemplified (Table 
4). 
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Table 3 - Potential toxicity of the best hits in each library, the squares in green shows best values while the red squares shows the worst values. Also, the yellow squares 
represent the intermediated values. 
Código ChemBridge 
AMES 
toxicity 
Max, tolerated dose 
(human) 
hERG I 
inhibitor 
Oral Rat Acute Toxicity 
(LD50) 
Oral Rat Chronic 
Toxicity (LOAEL) 
Hepato 
toxicity 
Minnow 
toxicity 
9072821 Yes -0.37 No 2.472 1.354 Yes 2.726 
9235556 No 0.463 No 2.564 0.836 Yes -0.054 
5925531 No -0.666 No 2.824 2.083 Yes 1.403 
9223087 No -0.225 No 2.464 0.971 Yes 3.469 
5277870 Yes -0.158 No 2.435 0.339 No 0.701 
9063888 Yes -0.343 No 2.674 0.979 Yes 4.338 
9120471* No 0.261 No 2.626 0.753 Yes 3.487 
9112974 No 0.229 No 2.582 0.891 Yes 3.652 
Código ZINC AMES toxicity 
Max, tolerated dose 
(human) 
hERG I 
inhibitor 
Oral Rat Acute Toxicity 
(LD50) 
Oral Rat Chronic 
Toxicity (LOAEL) Hepatotoxicity 
Minnow 
toxicity 
ZINC00968278 No -0.524 No 2.263 1.606 No 1.392 
ZINC00968278-2 
(Tautômero) No -0.494 No 2.322 1.443 No 1.233 
ZINC03830766* No 0.017 No 2.794 2.136 No -0.352 
ZINC00968276 No -0.524 No 2.263 1.606 No 1.392 
ZINC12503187 Yes 0.37 No 2.71 1.296 Yes 1.257 
ZINC00968276-2 
(Tautômero) No -0.494 No 2.322 1.443 No 1.233 
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Table 4 -Selected ligand in each library 
Library Ligand(compound) 2D Structure 
Exp N-[3-chloro-2-(4-ethyl-1-
piperazinyl)phenyl]-3-
ethoxybenzamide 
 
ChemBridge: 9120471  
Zdd 17-hydroxyestra-
1,3,5(10)-trien-3-yl 
benzoate 
 
 ZINC03830766 
  
 
4.4 Molecular Dynamics Analysis 
The prediction of root mean square deviation (RMSD), vacuum minimum energy 
and hydrogen bonds between protein and ligand were extracted from dynamics trajectory 
using specific tools from GROMACS analysis (ABRAHAM et al., 2015).  
Estradiol analog (ZINC03830766) prediction showed a low and similar root-
mean-square deviation (RMSD) to the known inhibitor extracted from the original (X25) 
NMT- ligand complex and NMT alone (PDB:4B13). Besides, low and stable RMSD 
results denotes protein-ligand complex stability along dynamics for each complex tested 
(Figure 4). 
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Figure 4 - Root mean square deviation in nanometers over the time for ZINC: 03830766 
(yellow), X25 (gray) and only NMT(dark blue) 
ZINC03830766-NMT complex featured a higher minimum energy (Figure 5), this 
fact can contribute for lower stability, but can be explained by the similarity with 
cholesterol structure, which has condensed chains with non-polar interactions  
which are more difficult to simulate  (RÓG et al., 2009).  
 
Figure 5 Energy(kJ/mol) over time (picoseconds) for X25 (blue) and ZINC:03830766 
(Yellow) 
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ZINC03830766-NMT complex also exhibited a similar hydrogen bonds profile in 
comparison with X25-NMT complex, which indicates more similar interactions profile 
over time (Figures 6,7,11). 
 
 
Figure 6- Number of Hydrogen bonds over the time (picoseconds) for X25 
 
Figure 7- Number of Hydrogen bonds over the time (picoseconds) for ZINC:03830766 
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Figure 8- Root mean square deviation in nanometers over the time for 
ChemBridge:9120471 (orange) X25(gray) and only NMT(light blue) 
ChemBridge Molecule 9120471 prediction showed a low and similar root-mean-
square deviation (RMSD) to known inhibitor extracted from the original (X25) NMT- 
ligand complex and NMT alone (PDB:4B13). Besides, low and stable RMSD results 
denotes protein-ligand complex stability along dynamics for each complex tested (Figure 
8). 
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The 9120471-NMT complex simulation showed a lower minimum energy (Figure 
9), which can contribute to compound stability over time. 
 
Figure 9- Energy(kJ/mol) over time(picoseconds) for X25(blue) and 
ChemBridge:9120471 (Orange) 
Hydrogen bonds profile prediction (Figure 10) was discrepant for known ligand 
(Figure 6 and 11), this fact can show us a different profile of interaction over the time. 
However, in the last frames, the number of hydrogen bonds and the minimum energy are 
similar in both complexes 9120471-NMT and X25-NMT. 
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Figure 10- Number of Hydrogen bonds over the time (picoseconds) for 
ChemBridge:9120471
 
Figure 11- Number of Hydrogen bonds over the time (picoseconds) for ZINC:03830766 
(gray), ChemBridge:9120471 (orange) and X25 (blue) 
4.5 2D Interaction protein-ligand and general discussion  
In the 2D diagrams, the Figures 12,13,14 show the interaction between known 
ligand over the dynamics frames 0,500 and 1000.The Figures 15,16,17 show the 
interaction between EXP ligand over the dynamics frames 0,500,1000, and Figures 
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18,19,20 show the interaction between ZDD ligand over the dynamics the frames 
0,500,1000 respectively. 
 
Figure 12- Frame 0:  Interactions between NMT and X25, the ligand molecule is 
indicated in purple on the active site of the enzyme, the dark red shapes indicate 
hydrophobic interactions with amino acids residues, green dashed lines indicate 
hydrogen bonds, brown lines indicate non-ligand bonds and purple ligand bonds, black 
balls corresponding atoms involved in hydrophobic contact. 
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Figure 13- Frame 500:  Interactions between NMT and X25, the ligand molecule is 
indicated in purple on the active site of the enzyme, the dark red shapes indicate 
hydrophobic interactions with amino acids residues, green dashed lines indicate 
hydrogen bonds, brown lines indicate non-ligand bonds and purple ligand bonds, black 
balls corresponding atoms involved in hydrophobic contact. 
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Figure 14- Frame 1000:  Interactions between NMT and X25, the ligand molecule is 
indicated in purple on the active site of the enzyme, the dark red shapes indicate 
hydrophobic interactions with amino acids residues, green dashed lines indicate 
hydrogen bonds, brown lines indicate non-ligand bonds and purple ligand bonds, black 
balls corresponding atoms involved in hydrophobic contact. 
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Figure 15 - Frame 0: Interaction between 9120471 and NMT, the ligand molecule is 
indicated in purple on the active site of the enzyme, the dark red shapes indicate 
hydrophobic interactions with amino acids residues, green dashed lines indicate 
hydrogen bonds, brown lines indicate non-ligand bonds and purple ligand bonds, black 
balls corresponding atoms involved in hydrophobic contact. 
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Figure 16 - Frame 500: Interaction between 9120471, the ligand molecule is indicated 
in purple on the active site of the enzyme, the dark red shapes indicate hydrophobic 
interactions with amino acids residues, green dashed lines indicate hydrogen bonds, 
brown lines indicate non-ligand bonds and purple ligand bonds, black balls 
corresponding atoms involved in hydrophobic contact. 
 24 
 
 
Figure 17- Frame 1000: Interaction between 9120471, the ligand molecule is indicated 
in purple on the active site of the enzyme, the dark red shapes indicate hydrophobic 
interactions with amino acids residues, green dashed lines indicate hydrogen bonds, 
brown lines indicate non-ligand bonds and purple ligand bonds, black balls 
corresponding atoms involved in hydrophobic contact. 
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Figure 18- Frame 0: Interaction between ZINC03830766 and NMT, the ligand molecule 
is indicated in purple on the active site of the enzyme, the dark red shapes indicate 
hydrophobic interactions with amino acids residues, green dashed lines indicate 
hydrogen bonds, brown lines indicate non-ligand bonds and purple ligand bonds, black 
balls corresponding atoms involved in hydrophobic contact. 
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Figure 19- Frame 500: Interaction between ZINC03830766 and NMT, the ligand 
molecule is indicated in purple on the active site of the enzyme, the dark red shapes 
indicate hydrophobic interactions with amino acids residues, green dashed lines indicate 
hydrogen bonds, brown lines indicate non-ligand bonds and purple ligand bonds, black 
balls corresponding atoms involved in hydrophobic contact. 
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Figure 20-Frame 1000: Interaction between ZINC03830766 and NMT, the ligand 
molecule is indicated in purple on the active site of the enzyme, the dark red shapes 
indicate hydrophobic interactions with amino acids residues, green dashed lines indicate 
hydrogen bonds, brown lines indicate non-ligand bonds and purple ligand bonds, black 
balls corresponding atoms involved in hydrophobic contact. 
 
In the 2D diagrams is also possible to see that the ligand ZINC03830766 show a 
profile of interactions with the amino acids very similar to X25, mainly for the hydrogen 
bond with the Tyr334 in both cases. The most part of the interactions of non-ligand 
residues involved in hydrophobic contact is maintained for all ligands. 
Estradiol and analogs showed already inhibition effect against protozoa 
influencing immune response, altering the response in a systemic pathway including 
innate immunity cells and adaptive immune response. Although the incidence of 
Plasmodium infections has not been intensively studied yet, females have been reported 
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a higher mortality rates even though the incidence between males and females seems the 
same. Pregnant women showed a greater risk than non-pregnant women, according to 
sex-hormones like estradiol, which can also create an immune response impairment 
(ROBERTS; WALKER; ALEXANDER, 2001). We hypothesize that estradiol and 
analogs though can potentially inhibit NMT and decreases parasite viability in an 
effective dose to inhibit the enzyme the systemic immune response is more prevalent. The 
systemic response showed to be more important than the inhibition of NMT, according 
to the estradiol levels in pregnant woman and the capacity of microbes to influence the 
hormones levels to improve their growth (VOM STEEG; KLEIN, 2017). 
The other compound tested on molecular dynamics (N-[3-chloro-2-(4-ethyl-1-
piperazinyl) phenyl]-3-ethoxybenzamide) (9120471) haven’t been synthetized and tested 
yet, according to the chemical library information and literature. 
 
5. CONCLUSION 
In this work, we simulate microenvironments and the interaction between protein 
and potential-ligands for Plasmodium vivax NMT. This study used the concept of 
alignment of known inhibitors to create sixteen shape-based models, which were 
validated, and the best were chosen to virtual screening, which was used performed a 
virtual screening using chosen libraries. Then the docking protein-ligand aided in the 
search for the best ligands for NMT. Further we elected the best potential ligands 
according their pharmacokinetics. The molecular dynamics were performed then the 
energy of the interaction, hydrogens bond interactions, and root mean square deviation 
between protein-ligand were studied. Thus, we could have selected from several more 
than 50 thousand compounds two potentially stable ligands for PvNMT, one of them 
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potentially safe (ChemBridge9120471) and other one with effects not so well known, 
these will test in future experiments. 
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